

Technology: [Treatment of retinal disorders with recombinant T cell receptor ligand \(RTL\)](#)

VA ID Number: 12-193

Inventor: Arthur Vandenbark

Location: Portland, OR

Topic: Genomics

USPTO Issue Date: 2/16/16

Patent Number: 9,260,506

This patent was assigned by the VA.

Contact

Lee Sylvers, PhD

lee.sylvers@va.gov

202-443-5646

Abstract

Methods are provided for the treatment of a retinal disorder or optic neuritis in a subject. In some embodiments, the methods include administering a therapeutically effective amount of an MHC molecule including covalently linked first, second, and third domains; wherein the first domain is an MHC class II .beta.1 domain and the second domain is an MHC class II .alpha.1 domain, wherein the amino terminus of the .alpha.1 domain is covalently linked to the carboxy terminus of the .beta.1 domain; or wherein the first domain is an MHC class I .alpha.1 domain and the second domain is an MHC class I .alpha.2 domain, wherein the amino terminus of the .alpha.2 domain is covalently linked to the carboxy terminus of the .alpha.1 domain; and wherein the third domain is covalently linked to the first domain and comprises a retinal antigen or an antigen of the central or peripheral nervous system.